Skip to Content
Print Save

Menactra (meningococcal conjugate vaccine) Disease Interactions

There are 3 disease interactions with Menactra (meningococcal conjugate vaccine):

Major

Vaccines (applies to Menactra) IM injection

Major Potential Hazard, Moderate plausibility. Applicable conditions: Thrombocytopenia, Thrombocytopathy, Coagulation Defect

In patients with thrombocytopenia or coagulation disorders, intramuscular injections may produce bleeding and hematomas. Patients with a platelet count less than 50,000/mm3 are at an increased risk. Caution is advised if the vaccine (e.g., plague vaccine, hepatitis A and B vaccines, and aluminum-adsorbed DTaP, DTP, DT, or Td) must be administered intramuscularly. The risk of bleeding may be minimized by vaccination immediately after the administration of replacement factor, use of a 23-gauge (or smaller) needle, and immediate application of direct pressure to the vaccination site for at least 2 minutes.

References

  1. "Product Information. Cholera vaccine (cholera vaccine)." Wyeth-Ayerst Laboratories, Philadelphia, PA.
  2. American Academy of Pediatrics. Committee on Infectious Diseases; Peter G, ed. "Red BooK: Report of the Committee on Infectious Diseases. 24th" Grove Village, IL: American Academy of Pediatrics (1997):
  3. "Product Information. Engerix-B (hepatitis B vaccine)." SmithKline Beecham, Philadelphia, PA.
  4. "Product Information. Havrix (hepatitis A vaccine)." SmithKline Beecham, Philadelphia, PA.
  5. "Product Information. Plague Vaccine (plague vaccine)." Greer Laboratories Inc, Lenoir, NC.
View all 5 references
Moderate

Meningococcal conjugate vaccine (applies to Menactra) GBS

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Guillain-Barre Syndrome

Persons previously diagnosed with Guillain-Barré syndrome (GBS) may be at increased risk of GBS following receipt of meningococcal conjugate vaccine. The decision to give this vaccine should take into account the potential benefits and risks.

Moderate

Vaccines (live attenuated/toxoid) (applies to Menactra) immunocompromised

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Immunodeficiency

The expected antibody responses may not be obtained when live attenuated vaccines and/or toxoids are administered to immunosuppressed persons, including those receiving immunosuppressive therapy. Caution and close monitoring is advised.

Menactra (meningococcal conjugate vaccine) drug interactions

There are 224 drug interactions with Menactra (meningococcal conjugate vaccine)

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer